Business Context and Reporting Period
This Form 8-K was filed by aTyr Pharma, Inc. on February 25, 2020. The report addresses Item 5.02 regarding the approval of 2019 bonus awards for the Company's named executive officers by the Board of Directors. These bonuses were previously omitted from the Summary Compensation Table in the Company's February 5, 2020 Prospectus because they had not yet been determined.
Key Financial Metrics
The filing does not provide corporate-level financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data presented relates to executive compensation for the years 2018 and 2019.
| Executive Officer | 2019 Total Compensation ($) | 2018 Total Compensation ($) |
|---|---|---|
| Sanjay S. Shukla, M.D., M.S. (CEO) | 663,961 | 1,380,465 |
| Jill M. Broadfoot (CFO) | 454,624 | 334,123 |
| Nancy E. Denyes (General Counsel) | 449,263 | Not Applicable |
Material Changes Versus Prior Period
- CEO Compensation: Total compensation for Sanjay S. Shukla decreased significantly from $1,380,465 in 2018 to $663,961 in 2019. This reduction is primarily driven by a decrease in Option Awards from $780,000 in 2018 to $82,400 in 2019.
- CFO Compensation: Total compensation for Jill M. Broadfoot increased from $334,123 in 2018 to $454,624 in 2019. This increase reflects her full-year tenure in 2019 compared to joining the company in July 2018.
- General Counsel: Nancy E. Denyes received $449,263 in 2019. She was promoted to General Counsel in February 2019 and did not serve as an executive officer in 2018.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding the Company's business operations or financial future. The document is strictly a disclosure of executive compensation adjustments. No risks or contingencies are discussed in this specific report.
Important Facts for Investors to Verify
- Verify the performance goals and milestones used by the Board to determine the 2019 bonus awards for executive officers.
- Review the February 5, 2020 Prospectus to understand the context of the previously omitted bonus figures.
- Confirm the valuation methodology for the equity-based awards (Stock and Option Awards) reported in the Summary Compensation Table.